Apr 252013
 

Life sciences companies in the U.S. raised roughly $404 million through ATMs in 2012, compared to $227 million in 2011, a 78 percent year-over-year increase.

In the fourth quarter of 2012, life sciences companies raised $128 million through ATMs, compared to $101 million in the third quarter, a 27 percent increase. This ATM activity included the following companies: StemCells Inc. (NASDAQ: STEM), Newark, Calif.; Sarepta Therapeutics Inc. (NASDAQ: SRPT), Cambridge, Mass.; Sunesis Pharmaceuticals Inc. (NASDAQ: SNSS), San Francisco, Calif.; Acadia Pharmaceuticals Inc. (NASDAQ: ACAD ), San Diego, Calif.

“The continued uptrend in ATM adoption and usage by life sciences companies is evident in these numbers,” says Todd Wyche, CEO of Brinson Patrick. “As we have predicted, an increasing number of life sciences companies continue to add ATMs to their financing toolkits to lower their cost of capital and avoid unnecessary dilution.”

ATM Proceeds - Life Sciences

 

 

 

Feb 202013
 

Todd Wyche was recently featured in Growth Capital Investor highlighting the differences between ATM offerings and equity lines. The three primary differences that the article focused on were the conditions to use the facilities, the method for determining the sales prices of the stock, and the upfront warrants or commitment shares. To read the full article, please click here, and if you would like to receive more information regarding our analysis, please feel free to contact us directly.

ATM Offerings vs. Equity Lines for Life Sciences

ATM Offerings vs Equity Lines Usage for Life Sciences

 

Jan 152013
 

It was an action packed week in San Francisco for the Brinson Patrick team, filled with meetings and networking with healthcare professionals attending the JP Morgan Healthcare Conference and Biotech Showcase.

Members of our investment banking team in attendance included Todd Wyche and Kevin Tyler. Also participating were research analysts Michael Higgins and Vernon Bernardino.

Todd Wyche, CEO of Brinson Patrick, sums up the experience: “…great opportunity to catch up with professionals that are passionate about the healthcare industry and hear about the new and exciting pipeline of products companies are looking to develop in 2013.”

The events were not all business. The 6th Annual Circus Before the Circus, co-sponsored by Brinson Patrick, allowed attendees to socialize over cocktails while watching gymnasts, acrobats and jugglers at the Four Seasons Hotel.

If you were not able to connect with us at the conference, please reach out to us now.

Dec 172012
 

At-the-market (ATM) offerings continue to show strong growth in the life sciences industry, with 29 agreements signed in 2012, compared to 18 agreements in 2011. Not only is it clear that companies are recognizing the benefits of accessing capital at a lower cost through the use of ATMs, there is also data that supports stock price change is less severe following ATM offering deal announcements compared to traditional follow-on deals.  On average, stock prices fall nearly 10% after ten days following traditional deal announcements, compared to 2.25% with ATM offerings. For an issuer with a market capitalization of $300 million, the price difference accounts for $21 million of additional dilution.

Data contains:

•    Deal timeframe: 1/1/2012 – 12/14/2012
•    Filter by issuer market cap: $30 million – $7 billion

Interested in viewing this ATM data segmented by market capitalization? Please connect via our contact page and we will send you our analysis.   

Oct 252012
 

On October 1, we kicked off the third quarter with the publication of two news articles featuring Todd Wyche, CEO of Brinson Patrick.

The first, published by Growth Capital Investor, provides insights into the recent surge of interest in ATM offerings. The published article, which can be viewed online here, describes the growth in use of this tool in the past few years and some of the advantages, such as cost savings, that companies find appealing.

In addition, we recently worked with Robert Hoffman, chief financial officer for Arena, to provide recommendations for CFOs as we approach the end of the year. This article, published in the October 1 issue of Genetic Engineering & Biotechnology News, describes the specific steps that can be taken to be well-prepared from a financial perspective.

Sep 252012
 

As we’ve said before, and throughout our website, for publicly traded life sciences companies, having at-the-market financing in the toolkit just makes sense. ATMs deliver control over the timing and amount of stock that reaches the market, giving life sciences organizations the flexibility to fund a clinical trial, make leveraged investments, ride the waves of an industry-specific event, and anything else that benefits from access to measured amounts of equity capital over time.

Here’s another benefit: ATM offerings provide the lowest cost of capital, too.

Life Science banking deals

Calculations

  • Deal timeframe: 1/1/2012 – 9/25/2012
  • Filter by issuer market cap: $30 million – $7 billion
  • Warrants cost calculated using Black Scholes European option pricing model
  • Market discount determined by calculating the percent change from the deal price and the stock price one day prior to deal announcement

Sep 142012
 

BioCentury NewsMakers Biotech Industry ConferenceMembers of our investment banking team – Todd Wyche, Kevin Tyler and Rada Milenovici attended the BioCentury NewsMakers Conference in New York earlier this month. Also in attendance were members of our research team – Vernon Bernardino and Michael Higgins.

The conference featured companies with major product and earnings events that are expected to play key roles in the life sciences industry. And in the words of conference organizers, it’s “…the best opportunity — in a single day — for the investment and pharma business development communities to assess the prospects for biotech stocks and to compare notes with key members of the institutional investment and analyst communities and pharma business development executives.” We’re always pleased to take part.

If you were not able to connect with us at the conference, please reach out to us now.

Sep 102012
 

We’re not clairvoyant, but we’re also not surprised that life science ATM financing slowed in the second quarter. There was a tremendous increase in all forms of follow-on offerings, including ATMs, in the first quarter of 2012, that went hand-in-hand with the stock market’s overall strong performance.

A summer slowdown doesn’t predict a trend to us: despite the decrease in capital raised, life science ATM sign-ups hit a quarterly record, and 50 life sciences companies now have ATMs available to raise capital when needed.

The growth trend is still in place, and some first-hand conversations we’ve had at recent life sciences events have us convinced that these firms are starting to recognize the benefits that ATMs bring to their financial toolkits.